United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coinbase

Meituan

Netflix

Pinduoduo Inc - ADR

JD.com

Cathie Wood-led Ark Invest on Wednesday trimmed all of its exposure to Netflix Inc (NASDAQ:NFLX) in one of the two active exchange-traded funds that own shares in the streaming video on-demand service.  The popular money managing firm sold 192 shares —estimated to be worth about $105,135— in Netflix via the Ark Next Generation Internet ETF (NYSE:ARKW).

Netflix, Pfizer, Coinbase, Pinduoduo, JD, Meituan — These Are Cathie Wood's Key Trades From Wednesday

Let's look at the ETFs that are well-poised to gain as Comirnaty's full FDA approval is likely to drive the vaccination rate.

ETFs to Rise on Full FDA Approval for Pfizer COVID-19 Vaccine

Johnson & Johnson

On Wednesday, both Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) shares edged lower to extend this week's declines despite reporting positive developments.  On Monday, the Pfizer/BioNTech covid-19 vaccine received full approval from the US Food and Drug Administration for use on people aged 16 years and over.

What's the better stock to buy: Pfizer or J&J?

BioNTech SE

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have initiated supplemental marketing application to the FDA seeking approval for its COVID-19 booster (third) shot. Earlier this week, Pfizer-BioNTech's COVID-19 Vaccine Became First To Receive Full FDA Approval.

Pfizer, BioNTech Now Seeking Full Approval For Third COVID-19 Vaccine Dose

BioNTech SE BNTX, +0.35% and Pfizer Inc. PFE, -2.03% said Wednesday that they initiated an application to U.S. regulators for a third dose of Comirnaty, their COVID-19 vaccine. BioNTech's stock was down 0.2% in trading on Wednesday, while Pfizer's stock fell 1.8%.

BioNTech, Pfizer initiate application for approval of a third dose of their COVID-19 vaccine

Days after the U.S. Food and Drug Administration issued its first full approval of a Covid-19 vaccine, other biotechs are moving forward with efforts to secure their vaccine's spot in the rapidly developing market.

Covid-19 Vaccine Makers Rush to Keep Up After Pfizer Gets FDA Approval

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of a booster (third) dose of COMIRNATY® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. The companies intend to complete submission of the sBLA by the end of this week. The sBLA includes data from a Phase 3 clin

Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older

Best Buy

Apple

Moderna

Northern Trust

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Best Buy among others.

Best Buy Among Today's Trending Stocks As Indices Trend Upward

Pfizer's COVID-19 vaccine got full FDA approval on Monday, including of its official name, Comirnaty - a combination of several different words.

The Pfizer vaccine's full name is Comirnaty - a hectic mashup of COVID-19, community, immunity, and mRNA

Alibaba

DraftKings

Block

Cathie Wood-led Ark Invest on Tuesday snapped up 1.07 million shares —estimated to be worth $60.6 million — in DraftKings Inc (NASDAQ:DKNG). Shares of the Boston, Massachusetts-based sports-betting company closed 5.91% higher at $56.47 on Tuesday after it announced a deal with the privately-held Simplebet, a specialty tech company that facilitates micro-betting.

DraftKings, Pfizer, Coinbase, Alibaba, Square, Pinduoduo — How Cathie Wood's Ark Played The Stock Market On Tuesday

Eli Lilly

Novo Nordisk

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)

The biotech space has once again come under the spotlight as the FDA has granted the first full U.S. approval to Pfizer (PFE)/BioNTech's (BNTX) coronavirus vaccine.

Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs

4:05pm: US equities close higher US stocks closed higher after Pfizer (NYSE:PFE)'s COVID-19 vaccine won full regulatory approval.  Both the S&P 500 and the Nasdaq closed at record highs.

US stocks close higher after Pfizer's COVID-19 vaccine wins full regulatory approval

Trillium Therapeutics

Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.

Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion

ProShares Ultra Nasdaq Biotechnology

The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officials are hoping will encourage those who have been reluctant to receive a vaccine to get vaccinated.

Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval

Virtus LifeSci Biotech Clinical Trials ETF

Loncar Cancer Immunotherapy ETF

Defiance Nasdaq Junior Biotechnology ETF

ALPS Medical Breakthroughs ETF

SPDR S&P Biotech ETF

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

Novavax

The euphoria over full FDA approval of the Pfizer-BioNTech vaccine appears to be waning.

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Sinking Today

Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks.

3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval

FDA Grants First Full Approval of COVID-19 Vaccine.

FDA Grants First Full Approval of COVID-19 Vaccine

Covid-19 vaccine stocks are back in focus, as cases in the U.S. surge with the spread of the highly infectious Delta variant of the virus. The seven-day average for Covid-19 cases stood at around 150,000 as of August 21, up by about 3x over the last month.

What Are The New Developments For Pfizer's Covid-19 Vaccine?

Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty becomes the first vaccine to be granted full approval by the FDA.

Pfizer (PFE)/BioNTech Comirnaty Gets FDA's Full Approval

Employers announced a wave of Covid-19 vaccine mandates in the hours after the U.S. Food and Drug Administration issued full approval of Pfizer's Covid-19 vaccine.

Covid-19 Vaccine Mandates Spread After FDA Approval of Pfizer's Vaccine

Since 2020, investors have been rallying behind shares of Pfizer and Germany's BioNTech, two companies that were poised to play a crucial role in helping bring an end to a devastating pandemic. Those bets have paid off.

Pfizer's FDA approval is boosting these stocks

One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 150,000 shares of Pfizer Inc.

Cathie Wood's ARK Invest Buys Over 160,000 Shares of Pfizer

Blackstone Group

ConocoPhillips

EOG Resources

MetLife

We have narrowed down our search to five large-cap stocks (market capital >$30 billion) that have popped more than 30% year to date. These are: AIG, MET, BX, COP and EOG.

News for Pfizer Stock (PFE)